Carboplatin, a newer platinum analog can be administered We evaluated the therapeutic value of sequential cyclical hor-on an outpatient basis, is well tolerated, and produces fewer monal therapy (megestrol acetate, and tamoxifen citrate) plus sin-side effects than cisplatin [9, 10] . Two phase II trials involvgle-agent chemotherapy (carboplatin) in the outpatient manage-ing carboplatin produced responses of 28 and 33% with ment of advanced or recurrent endometrial cancer. Carboplatin median survival similar to that of single-agent doxorubicin (300 mg/m 2 ) was administered every 4 weeks for six courses or or cisplatin [11, 12] . Carboplatin was chosen as the single until disease progression. In addition, patients alternated meges-cytotoxic agent in this trial designed for outpatient adminis- Endometrial adenocarcinoma is hormonally sensitive. Seven of 13 patients experienced a hematologic toxicity (six grade Progestational agents produce a 15-20% response rate, with 2, one grade 3); all resolved within 2 weeks. Dose reduction of median survival ranging 9 to 20 months [13] [14] [15] [16] . Assays carboplatin to 200 mg/m 2 was required in one patient. No other for estrogen and progesterone receptors display a clear corretoxicities were encountered. The median survival for all patients lation between histologic grade and receptor status [14, 15] .
INTRODUCTION
progestin treatment leads to depletion of progesterone recepEndometrial cancer is the most common invasive malig-tors (PR) in the target tissue with a short duration of response nancy of the female genital tract in the United States [1] . [21, 22] . Tamoxifen increases PR concentration in animal Standard treatment includes surgical staging with postopera-models and in human endometrial tissue, and may enhance tive pelvic radiotherapy for patients at high risk for recur-the response of endometrial cancer to MA, with minimal rence [2] . Despite high cure rates, a significant number of toxicity [22] [23] [24] [25] [26] [27] [28] . patients have advanced disease or develop metastasis, requirThis study evaluates the therapeutic value of adding a ing systemic therapy [3] . Several agents including doxorubi-sequential cyclical hormonal regimen (megestrol acetatecin, platinum, Taxol, cyclophosphamide, and ifosfamide tamoxifen citrate) to single-agent chemotherapy (carhave demonstrated activity against endometrial cancer [1-boplatin) in the outpatient management of advanced or recur -5] . Doxorubicin was the most studied single cytotoxic agent rent endometrial cancer. for advanced and recurrent endometrial cancer, with response rates ranging 20-40% [1, 7] . Previous studies have MATERIALS AND METHODS shown similar response rates with cisplatin as single-agent treatment, and combination cytotoxic chemotherapies have Patients with histologically documented endometrial carcinoma extending outside of the pelvis at primary diagnosis shown no advantage over single-agent therapy [4, [6] [7] [8] . mandated by the adverse effects, which were defined by the All primary endometrial cancers were staged and graded GOG common toxicity criteria [31] . Treatment was continaccording to the revised FIGO surgical staging classification ued for a maximum of 6 courses of carboplatin or until [30] . If metastatic lesions were present, they were biopsied the disease progressed. Patients with unacceptable adverse and a histologic grade was assigned. If a patient had her effects were removed from the study. No dosage modificainitial surgery elsewhere, our pathologist confirmed the diagtions were permitted for the tamoxifen or the megestrol acenosis and reviewed the slides. A gynecologic oncologist retate. viewed all operative reports, and confirmed or assigned a
The objective clinical response of each patient was docusurgical stage when possible. CA-125 and CEA tumor markmented and classified as complete, partial, stable, or indicaers were obtained preoperatively on all patients with primary tive of increasing disease. Progression-free interval and surendometrial cancer or at disease recurrence and followed vival were also determined for the patients enrolled in the every 4 weeks if elevated. The patient was assessed monthly study (Table 1) . Statistical analysis was performed using the for clinical response by physical examination, performance SPSS statistical package, using the Mantel-Haenszel x 2 test status, and evaluation of laboratory testing. Documentation to evaluate the linear by linear associations between patient of the disease status was recorded monthly. A routine PA characteristics and outcomes. and lateral chest X ray was performed quarterly (monthly if lung metastases were present).
Estrogen and progesterone receptors (ER/PR) were ob-RESULTS tained on original hysterectomy specimens, or if not available, on biopsy tissue from the documented recurrence prior Eighteen patients were enrolled between June 1990 and July 1993. Of these, 13 (72.2%) were considered evaluable. to administration of treatment drugs. Immunohistochemical staining of ER and PR was performed on formalin-fixed, Five patients were not evaluable for the following reasons: two patients were lost to follow-up after the first or second paraffin-embedded 5-mm-thick sections using an antigen retrieval technique and monoclonal antibodies [35] . Positively course of therapy, making evaluation of response impossible.
One patient refused treatment after one course despite a immunostained nuclei were indicated by a brown color and were quantitated at 401 magnification in an image analyzer, partial response. One patient was removed from the study due to an adverse reaction (flushing). One patient was not referring institution). Original hysterectomy specimens were available for six patients; receptor status was obtained from compliant with hormonal therapy; however, she had a complete response after three courses of carboplatin and contin-biopsied recurrences in five patients for whom the original specimens were unobtainable. Four patients (30.8%) were ued on MA alone with a disease-free interval of 38 months.
Of the evaluable patients (N Å 13), the mean age was ER/PR positive (two from hysterectomy specimens, two from recurrences); one of these displayed a weakly positive 63.2 years with a range of 37 to 72 years. Response was not related to age (P Å 0.65). Table 2 lists the characteristics ER on the original hysterectomy specimen. Seven patients (53.8%) were ER/PR negative (four from hysterectomy, and data for each patient, and Table 3 displays the location of recurrent or metastatic disease and response for each site. three from recurrence, Table 2 ).
All patients had a prior hysterectomy (total abdominal in Seven of 13 patients (54%) had vaginal disease upon study enrollment. Five (38.5%) patients had disease in multiple 11, modified radical in 1, and radical hysterectomy in 1 patient) and 7 patients (53.8%) had a lymphadenectomy as sites. Three patients had an isolated vaginal recurrence (23.1%).
well. Eleven patients underwent previous teletherapy, five received brachytherapy, four patients had previous chemoEstrogen and progesterone receptor status was obtained in 11 patients. Status was unobtainable for two patients (pa-therapy, and one patient received intraperitoneal P32 installation. thology specimen blocks had been discarded or lost by the Of the 18 patients initially enrolled, adverse effects in-response and is progression-free for 59 months. The other cluded a flushing reaction in one patient, which prevented three previously treated patients also had papillary serous further therapy with megestrol acetate. Three patients experi-carcinomas. One patient had a partial response and has stable enced Grade 2-3 neutropenia or sepsis (16.7%), one patient disease at 21 months from enrollment. One patient had a experienced Grade 3 anemia requiring transfusion (5.6%), partial response for 3 months, then progressed and died 6 and five patients (27.8%) experienced Grade 2 thrombocyto-months from study enrollment. One patient exhibited no penia. The adverse effect resulted in delay of chemotherapy response, and survived 9 months (Table 2) . in five patients. In four of the five patients whose chemotherAll ER/PR-positive patients responded to therapy (comapy was delayed, the thrombocytopenia had resolved by Day plete in three, partial in the one patient with the weakly 42 of the cycle. In one patient neutropenia delayed therapy positive receptors). Five of the seven (71.4%) ER/PR-negaby 7 days. One patient was dose escalated after the first tive patients exhibited a partial response. The ER/PR-posicourse of carboplatin; however, she required dosage reduc-tive patients had better outcomes (P Å 0.04) and better surtion to the 300 mg/m 2 dosage for the remaining courses. vival (P õ 0.01) than ER/PR-negative patients, with a meOne additional patient required a dosage reduction to 200 dian survival of 25 months. Median survival was 9 months mg/m 2 due to persistent thrombocytopenia after the first for ER/PR-negative patients (Table 2 ). course and was maintained at that dose for the remaining Of the seven patients who presented with vaginal disease five courses. The responses and progression-free intervals (54% of the total study population), 4 patients (57.1%) for all evaluable patients are presented in Table 4 . Four achieved a complete response. Two patients (28.6%) patients (30.8%) achieved a complete response for at least achieved a partial response, and one patient (14.3%) had a 8 weeks. Six patients (46.2%) achieved a partial response stable response for 3 months. No patients demonstrated clinias defined by decrease of disease size on clinical examination cal worsening within the first month of therapy. All patients or radiographic evaluation. One patient (7.7%) had no with vaginal disease had received prior radiation therapy and change in disease status for a 3-month period before devel-four patients had received brachytherapy as well (Tables 2 oping progressive disease. Two patients (15.4%) demon-and 3). There was no relation between response and disease strated no response to the study drugs.
site, although patients with an isolated vaginal recurrence Four patients had prior chemotherapy; one had a complete had better responses (P Å 0.04). The progression-free interval was calculated for all pa- Adriamycin, and cisplatin chemotherapy) and has no evi- 4 to 42% [4, 5, 7, 8] . For combination therapies in randomized trials, the responses range from 30 to 80% [6, 8] . Progestins alone have a 15-20% response in recent studies [10-13, 16, 19] . and then recurred and died 25 months after study enrollment.
Combinations of cytotoxic chemotherapy with hormones One patient has remained disease-free for 59 months. produce higher response rates, ranging from 19 to 80%; Overall survival of the 13 evaluable patients is demonhowever, the duration of response is short (4-8 months) strated in Table 5 . Ten patients (76.9%) died of disease without a clear survival advantage [16, 17, 21, 33, 34] . Our with a median survival of 7.8 months. One patient (7.7%) results (77% response, 11 months median survival) are simiis currently alive with stable disease at 21 months from study lar and support further investigations with larger patient popenrollment. Two patients (15.4%) are currently alive with ulations. no evidence of disease with at 41 and 59 months from study Our data show a significant relationship between receptor enrollment. Overall survival is 23% and is improved for positivity and patient response and survival. The scientific responding patients (P Å 0.045). Median survival is 33 explanation and the exact mechanism resulting in the immonths for complete responders, 8.5 months for partial reproved response is unknown, but appears related to the addisponders, and 8 months for nonresponders. The median surtion of hormones to the regimen. The ''tumor resistance'' vival for all 13 patients is 11 months (5-59 months).
seen with continued administration of progestins appears to The degree of response and the interval from initial diagbe related to depletion and downregulation of progesterone nosis of endometrial cancer to the diagnosis of recurrence receptors. These receptors reappear upon withdrawal of the and study enrollment is displayed in Table 6 . Five patients hormone, suggesting that intermittent progestin administra-(38.5%) recurred within the first year, 9 (69%) by the second tion may improve the therapeutic effect. Tamoxifen has been year, and 11 (84.6%) within the first 3 years. The median shown to enhance the antitumor effects of progestins in nude interval to recurrence was 15 months for all evaluable pamouse models. Combination therapy may allow regeneration tients. There was no relationship between the time to recurof receptors and therefore enhance and prolong response. rence and patient response to therapy (P Å 0.54).
Basic science and translational research are in progress to elucidate the mechanism by which this regimen exerts its DISCUSSION effects on the molecular level. A current Gynecologic Oncology Group study nearing completion (protocol 153) will help Carboplatin combined with alternating courses of megestrol acetate and tamoxifen resulted in a 77% response rate to determine the clinical response to the alternating courses of tamoxifen and megestrol acetate alone [13] [14] [15] [16] [22] [23] [24] [25] [26] [27] [28] . (30.8% complete, 46.2% partial) in 13 patients. There was no relation between the response to this therapy and age, This phase II study of 13 patients shows a significant prior chemotherapy, initial stage, histology, or grade of tumor. There was also no relation between response and dis- 
